Literature DB >> 6423374

Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome).

K Yamamoto, I Maeyama, H Kishimoto, Y Morio, Y Harada, K Ishitobi, J Ishikawa.   

Abstract

A 12-year-old Japanese girl with polyostotic fibrous dysplasia and endocrine concomitants, was treated with elcatonin, a synthetic eel calcitonin analogue, 10 MRC unit/twice a week given by intramuscular injection. Significant decreases in 24 hr urinary content of hydroxyproline and other amino acids from bone collagen were observed during the course of treatment over 5 months. This biochemical result suggests that the synthetic eel calcitonin analogue exhibits the therapeutic effect in patients with polyostotic fibrous dysplasia by inhibiting bone resorption.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6423374     DOI: 10.1507/endocrj1954.30.651

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  3 in total

1.  [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].

Authors:  J Pfeilschifter; R Ziegler
Journal:  Med Klin (Munich)       Date:  1998-06-15

Review 2.  Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.

Authors:  Marlous Rotman; Neveen Agnes Therese Hamdy; Natasha M Appelman-Dijkstra
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

3.  Effect of Intranasal Calcitonin in a Patient with McCune-Albright Syndrome, Fibrous Dysplasia, and Refractory Bone Pain.

Authors:  Tayane Muniz Fighera; Poli Mara Spritzer
Journal:  Case Rep Endocrinol       Date:  2017-06-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.